Huang WW - Search Results

1

Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.

Huang WW, Huang C, Liu J, Zheng HY, Lin L. Huang WW, et al. Among authors: huang c. PLoS One. 2012;7(7):e40783. doi: 10.1371/journal.pone.0040783. Epub 2012 Jul 26. PLoS One. 2012. PMID: 22844410 Free PMC article. Review.

2

[mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR].

Zheng HY, Chen Q, Ye YB, Huang WW. Zheng HY, et al. Among authors: huang ww. Zhonghua Yi Xue Za Zhi. 2008 Aug 19;88(32):2267-70. Zhonghua Yi Xue Za Zhi. 2008. PMID: 19087676 Chinese.

3

The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients.

Huang W, Liu J, Wu F, Chen K, Li N, Hong Y, Huang C, Zhen H, Lin L. Huang W, et al. Oncotarget. 2016 May 24;7(21):31501-7. doi: 10.18632/oncotarget.8967. Oncotarget. 2016. PMID: 27129172 Free PMC article.

4

The effect analysis of CYP2D6 gene polymorphism in the toremifene and tamoxifen treatment in patient with breast cancer.

Zeng Y, Huang K, Huang W. Zeng Y, et al. Pak J Pharm Sci. 2017 May;30(3(Special)):1095-1098. Pak J Pharm Sci. 2017. PMID: 28671087 Clinical Trial.

5

Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.

Huang W, Liu J, Zeng Y, Wu F, Li N, Chen K, Hong Y, Wang L, Zhen H, Lin L. Huang W, et al. Cancer Chemother Pharmacol. 2018 Oct;82(4):607-613. doi: 10.1007/s00280-018-3639-z. Epub 2018 Jul 24. Cancer Chemother Pharmacol. 2018. PMID: 30043207 Clinical Trial.

6

Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway.

Wang LL, Huang WW, Huang J, Huang RF, Li NN, Hong Y, Chen ML, Wu F, Liu J. Wang LL, et al. Among authors: huang rf, huang ww, huang j. Kaohsiung J Med Sci. 2020 Aug;36(8):581-591. doi: 10.1002/kjm2.12212. Epub 2020 Apr 20. Kaohsiung J Med Sci. 2020. Retraction in: Kaohsiung J Med Sci. 2023 Dec 13. doi: 10.1002/kjm2.12790. PMID: 32311203 Free article. Retracted.

7

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer.

Huang W, Li C, Chen M, Lin D, Wu F, Chen X, Li N, Wang L, Liu J. Huang W, et al. Onco Targets Ther. 2020 Aug 5;13:7785-7792. doi: 10.2147/OTT.S253333. eCollection 2020. Onco Targets Ther. 2020. PMID: 32943874 Free PMC article.

8

Corrigendum to "Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway" [Kaohsiung J Med Sci. 2020;36(8):581-591].

Wang LL, Huang WW, Huang J, Huang RF, Li NN, Hong Y, Chen ML, Wu F, Liu J. Wang LL, et al. Among authors: huang rf, huang ww, huang j. Kaohsiung J Med Sci. 2022 Mar;38(3):288. doi: 10.1002/kjm2.12525. Kaohsiung J Med Sci. 2022. PMID: 35286015 Free article. No abstract available.

9

Tumor mutational burden in non-immunotherapy patients with heavily pretreated metastatic breast cancer: long-term outcomes from a single institution.

Wu F, Chen M, Li N, Wu X, Huang W, Chen X, Chen K, Wang L, Liu J. Wu F, et al. J Chemother. 2023 Jul;35(4):348-356. doi: 10.1080/1120009X.2022.2107753. Epub 2022 Aug 24. J Chemother. 2023. PMID: 36000459

10

Application of oncolytic virus in tumor therapy.

Huang Z, Guo H, Lin L, Li S, Yang Y, Han Y, Huang W, Yang J. Huang Z, et al. J Med Virol. 2023 Apr;95(4):e28729. doi: 10.1002/jmv.28729. J Med Virol. 2023. PMID: 37185868 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

277 results

Search Page